根据最新的财务报表(Form-10K),RADNOSTIX, INC. 的总资产为 $0,净损失为 $0
INIS 的关键财务比率是什么?
RADNOSTIX, INC. 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
RADNOSTIX, INC. 的收入按细分市场或地理位置如何划分?
RADNOSTIX, INC. 最大收入来源是 Theranostics,在最近的收益报告中收入为 6,841,094。就地区而言, United States 是 RADNOSTIX, INC. 的主要市场,收入为 13,070,336。
RADNOSTIX, INC. 是否盈利?
不,根据最新的财务报表,RADNOSTIX, INC. 的净损失为 $0
RADNOSTIX, INC. 有负债吗?
不,RADNOSTIX, INC. 的负债为 0
RADNOSTIX, INC. 的流通股有多少?
RADNOSTIX, INC. 的总流通股为 0
关键数据
前收盘价
$0.08
开盘价
$0.08
当日区间
$0.08 - $0.083
52周范围
$0.038 - $0.11
交易量
3.4K
平均成交量
61.1K
股息收益率
--
每股收益(TTM)
-0.00
市值
$42.2M
什么是 INIS?
Radnostix, Inc. engages in the manufacture of nuclear medicine calibration and reference standards cobalt tele therapy sources, as well as radioisotopes and radiochemical for medical research and clinical devices. The company is headquartered in Idaho Falls, Idaho and currently employs 44 full-time employees. The firm manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. The firm provides contract manufacturing of various drug products as well as radioisotope active pharmaceutical ingredient (API) supply for third party theranostics clients. The firm manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and single photon emission computed tomography (SPECT)/positron emission tomography (PET) imaging systems as well as industrial calibration standards under its RadQual brand. The firm also manufactures Cobalt-60 sealed source products.